Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Issue: Health products
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 1 - 15 of 19 items.
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
AlertHealth professional risk communication | 2021-06-29
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
AlertHealth professional risk communication | 2021-03-24
Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2021-03-01
Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels (US-Labelled Supply)
AlertHealth professional risk communication | 2021-03-31
Archived – Important Safety Information Regarding Accolate® (Zafirlukast) and Hepatic Effects – AstraZeneca
AlertHealth professional risk communication | 2002-12-18
Important Safety Information on Oxeze (formoterol fumarate dihydrate) Turbuhaler – AstraZeneca Canada Inc. – For Health Professionals
AlertHealth professional risk communication | 2005-09-09
Association of CRESTOR® (rosuvastatin) with Muscle -Related Adverse Events – AstraZeneca Canada Inc. – For Health Professionals
AlertHealth professional risk communication | 2005-03-11
Archived – Important Safety Information Regarding Medication Errors Resulting from Confusion Between Seroquel® and Serzone-5HT2® – AstraZeneca and Bristol-Myers Squibb
AlertHealth professional risk communication | 2002-10-31
Pulmicort Nebuamp - (0.125 mg/mL, 0.25 mg/mL, 0.5 mg/mL)
RecallHealth product recall | 2013-02-18
Archived – Important Safety Information Regarding the Association Between CRESTOR (Rosuvastatin) and Rhabdomyolysis
AlertHealth professional risk communication | 2004-06-22
Lynparza® (2018-02-23)
RecallHealth product recall | 2018-02-23
FASLODEX (fulvestrant) - Risk of Unnecessary Therapy Modification due to Falsely Elevated Estradiol Levels
AlertHealth professional risk communication | 2016-10-18
Important Safety Information Regarding Reports of Serious Hepatic Events in Patients Receiving ACCOLATE® (Zafirlukast) – For Health Professionals
AlertHealth professional risk communication | 2004-04-19
SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic Ketoacidosis
AlertHealth professional risk communication | 2016-05-16
MULTISTIX 10SG (2015-06-24)
RecallHealth product recall | 2015-08-11